file,ref_number,ref_text,doi,doi_url,titleDoi,firstAuthDoi,author_similarity,title_similarity
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[1],National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021.,10.1111/j.1759-7714.2010.00016.x,https://doi.org/10.1111/j.1759-7714.2010.00016.x,"Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009",Xu,2,93
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[2],"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330-338.",10.1038/nrc1074,https://doi.org/10.1038/nrc1074,5-Fluorouracil: mechanisms of action and clinical strategies,Longley,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[3],"Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., ... & Nordlinger, B. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27(8), 1386-1422.",10.1093/annonc/mdu260,https://doi.org/10.1093/annonc/mdu260,"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",Van Cutsem,100,65
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[4],"Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., ... & Taube, J. M. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.",10.1056/nejmoa1500596,https://doi.org/10.1056/nejmoa1500596,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency,Le,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[5],"Meacham, C. E., & Morrison, S. J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature, 501(7467), 328-337.",10.1038/nature12624,https://doi.org/10.1038/nature12624,Tumour heterogeneity and cancer cell plasticity,Meacham,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[6],"Compton, C. C. (2007). Optimal pathologic staging: defining stage II disease. Clinical Cancer Research, 13(22), 6862s-6870s.",10.1158/1078-0432.ccr-07-1398,https://doi.org/10.1158/1078-0432.ccr-07-1398,Optimal Pathologic Staging: Defining Stage II Disease,Compton,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[7],"Chaffer, C. L., & Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science, 331(6024), 1559-1564.",10.1126/science.1203543,https://doi.org/10.1126/science.1203543,A Perspective on Cancer Cell Metastasis,Chaffer,100,100
experiments/crc/ai_messages/high_complexity--crc_apc_impact_2020_11,[8],"Jayne, D. G., Fook, S., Loi, C., & Seow-Choen, F. (2002). Peritoneal carcinomatosis from colorectal cancer. British Journal of Surgery, 89(12), 1545-1550.",10.1046/j.1365-2168.2002.02274.x,https://doi.org/10.1046/j.1365-2168.2002.02274.x,Peritoneal carcinomatosis from colorectal cancer,Jayne,100,100
